Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cilobradine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 known ✓ | Q9Y3Q4 | 3/20 | 0.56 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.42 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.42 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.42 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.42 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilobradine SCHEMBL29896706 | 1.00 | CYP3A4 (0.58) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| Cilobradine SCHEMBL9518220 | 1.00 | CYP3A4 (0.58) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| Cilobradine SCHEMBL1855245 | 0.99 | HCN4 (0.57) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| Cilobradine SCHEMBL30169956 | 0.99 | HCN4 (0.57) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| Cilobradine SCHEMBL628133 | 0.99 | HCN4 (0.57) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| Cilobradine SCHEMBL9740702 | 0.98 | HCN4 (0.56) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| Hydrochloric Acid SCHEMBL9739678 | 0.97 | CYP3A4 (0.57) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| SCHEMBL9740314 | 0.95 | HCN4 (0.53) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| SCHEMBL9739258 | 0.94 | DHCR7 (0.57) | CYP3A4ALOX15HCN4MAPTDHCR7 | |
| SCHEMBL9742193 | 0.94 | HCN4 (0.52) | CYP3A4ALOX15HCN4MAPTDHCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318247-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | Boehringer Ingelheim Vetmedica GmbH (DE) | 2018-05-09 | — | — | EP | claimed |
| EP-2741736-B1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2017-11-22 | — | — | EP | claimed |
| EP-2953612-A1 | KIT-OF-PARTS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2015-12-16 | — | — | EP | claimed |
| US-20140227351-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| WO-2014122248-A1 | KIT-OF-PARTS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-08-14 | — | — | WO | claimed |
| US-20140224680-A1 | KIT-OF-PARTS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| EP-2741736-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | Boehringer Ingelheim Vetmedica GmbH (DE) | 2014-06-18 | — | — | EP | claimed |
| US-8741350-B2 | Taste masked pharmaceutical composition | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-06-03 | — | — | US | claimed |
| US-20130084332-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-04-04 | — | — | US | claimed |
| WO-2013024023-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-02-21 | — | — | WO | claimed |
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-20130084332-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-04-04 | — | — | US | disclosed |
| WO-2013024036-A1 | FUNNY CURRENT (IF) INHIBITORS FOR USE IN A METHOD OF TREATING AND PREVENTING HEART FAILURE IN FELINE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024023-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
| US-20130040937-A1 | INHIBITORS FOR TREATING AND PREVENTING HEART FAILURE IN FELINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | HCN4 4075/4885GAA 3044/4885CHRM2 2505/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | HCN4 3236/4885GAA 43/4885CHRM2 3591/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | HCN4 4075/4885GAA 3044/4885CHRM2 2505/4885 |
| US-20130084332-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | TAS2R50, TAS2R40, TAS2R42 | HCN4 1074/4885GAA 319/4885CHRM2 329/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | HCN4 4075/4885GAA 3044/4885CHRM2 2505/4885 |
| US-20140224680-A1 | KIT-OF-PARTS | KIT, SAMM50, CUTA | HCN4 4094/4885GAA 2820/4885CHRM2 2638/4885 |
| US-20140227351-A1 | TASTE MASKED PHARMACEUTICAL COMPOSITION | TAS2R50, TAS2R40, TAS2R30 | HCN4 1199/4885GAA 345/4885CHRM2 332/4885 |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | MKI67, CDK4, CDKN1A | HCN4 2327/4885GAA 1914/4885CHRM2 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.